A new clinical trial has launched to test a promising treatment for patients with recurrent glioblastoma, one of the most aggressive forms of brain cancer.
The Phase 1/2 trial, led by biotechnology company Carthera and academic partners at AP-HP and Inserm, seeks to evaluate the safety and efficacy of using the SonoCloud-9 device in combination with intravenous carboplatin chemotherapy. This approach uses ultrasound technology to temporarily open the blood-brain barrier, allowing more of the chemotherapy drug to reach the tumor.
Dr. Sonia Alamir, Principal Investigator at Hôpital de la Pitié-Salpêtrière in Paris, explained the need for innovation in this area: “Patients with recurrent glioblastoma have limited therapeutic options. We are excited to open this new clinical trial and explore the benefit of ultrasound-induced blood-brain barrier opening with carboplatin, a chemotherapy drug commonly used for other cancer types but unable to cross into the brain at effective levels.”
The trial is sponsored by Carthera with support from the European Innovation Council (EIC) Accelerator and the French National Research Agency (ANR). Up to 30 patients in France will be enrolled in the study. Initial safety data are expected in early 2025.
